MetaHeps
Martinsried
About MetaHeps
MetaHeps GmbH provides consulting and solutions for drug-induced liver injury (DILI) in clinical drug-development and postmarketing. It is a unique service provider that generates a personalized cell model reflecting individual drug hepatotoxicity from a small patient blood sample. Customers are research driven pharmaceutical companies and global acting CROs, using Metaheps’ services in clinical phases of drug development as well as postmarketing to diagnose or exclude Druginduced liver injury (DILI) in individual patients. MetaHeps vision is to increase access of patients to novel drugs by addressing DILI issues in drug development in an unrivaled and innovative approach.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Last round: Grant (Jan 2019)
- Website: metaheps.com
- Phone: +49089440073130
Industries & Categories
Biotechnology, Consulting, Health Care
Social Profiles
Canonical: https://fsome.com/organization/metaheps-302525 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.